NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has signed an agreement making Rhenium the exclusive distributor of its RosettaGx Reveal thyroid cancer diagnostic in Israel.

Reveal is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.